pecified Drug-use Survey of Lotriga Granular Capsules: OCEAN3 (Outcome Prevention on Cardiovascular Events by Antihyperlipidemic Therapy With N3-fatty Acid in Japan)

Trial Profile

pecified Drug-use Survey of Lotriga Granular Capsules: OCEAN3 (Outcome Prevention on Cardiovascular Events by Antihyperlipidemic Therapy With N3-fatty Acid in Japan)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications Hyperlipidaemia
  • Focus Therapeutic Use
  • Acronyms OCEAN3
  • Sponsors Takeda
  • Most Recent Events

    • 14 Nov 2017 Planned primary completion date changed from 30 Sep 2019 to 31 Dec 2019.
    • 14 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Nov 2017 Planned number of patients changed from 14000 to 15331.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top